| Outcome Measures: |
Primary: Intrahepatic fat, intrahepatic fat change from baseline by quantitative ultrasound, -7±3days; 168±3days | Secondary: Liver function, serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST), -7±3days; 28±3days; 84±3days; 168±3days|Lipid, total cholesterol (CH), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL), -7±3days; 28±3days; 84±3days; 168±3days|Plasma glucose in standard meal tolerance test, plasma glucose was measured at 0, 30, 60, and 120 min after ingestion of the meal, -7±3days; 168±3days|Plasma insulin in standard meal tolerance test, plasma insulin was measured at 0, 30, 60, and 120 min after ingestion of the meal, -7±3days; 168±3days|Glucose control, fasting blood glucose (FBG), postprandial blood glucose (PBG), 14±3days; 28±3days; 56±3days; 84±3days; 112±3days; 140±3days; 168±3days|HbA1c, glycosylated hemoglobin A 1c (HbA1c) was measured by high-performance liquid chromatography, -7±3days; 84±3days; 168±3days|Body composition, fat mass and lean tissue were measured by dual-energy X-ray absorptiometry, -7±3days; 168±3days|Weight, body weight, 14±3days; 28±3days; 56±3days; 84±3days; 112±3days; 140±3days; 168±3days|WC, waist circumference, 14±3days; 28±3days; 56±3days; 84±3days; 112±3days; 140±3days; 168±3days | Other: Number of Participants with gliclazide, liraglutide or metformin adverse events as a measure of safety and tolerability, adverse events caused by the drugs, -7±3days; 0±3days; 14±3days; 28±3days; 56±3days; 84±3days; 112±3days; 140±3day;168±3days
|
